P
Peter Fritz
Researcher at Robert Bosch Hospital
Publications - 110
Citations - 7734
Peter Fritz is an academic researcher from Robert Bosch Hospital. The author has contributed to research in topics: Peritoneal dialysis & Breast cancer. The author has an hindex of 37, co-authored 99 publications receiving 7168 citations. Previous affiliations of Peter Fritz include Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Bernd Greiner,Michel Eichelbaum,Peter Fritz,Hans-Peter Kreichgauer,Oliver von Richter,Johannes Zundler,Heyo K. Kroemer +6 more
TL;DR: Concomitant administration of rifampin reduced digoxin plasma concentrations substantially after oral administration but to a lesser extent after intravenous administration, and induction of intestinal P-gp could explain this new type of drug-drug interaction.
Journal ArticleDOI
Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis
Heiko Mahrholdt,Anja Wagner,Claudia C. Deluigi,Eva Maria Kispert,Stefan Hager,Gabriel Meinhardt,Holger Vogelsberg,Peter Fritz,Juergen Dippon,C.-Thomas Bock,Karin Klingel,Reinhard Kandolf,Udo Sechtem +12 more
TL;DR: The data indicate that PVB19 and HHV6 are the most important causes for viral myocarditis in Germany and that the clinical presentation is related to the type of virus.
Journal ArticleDOI
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits,Margaretha Rudas,Raimund Jakesz,Peter Dubsky,Florian Fitzal,Christian F. Singer,Otto Dietze,Richard Greil,Andrea Jelen,Paul Sevelda,Christa Freibauer,Volkmar Müller,Fritz Jänicke,Marcus Schmidt,Heinz Kölbl,Achim Rody,Manfred Kaufmann,Werner Schroth,Hiltrud Brauch,Matthias Schwab,Peter Fritz,Karsten Weber,Inke Sabine Feder,Guido Hennig,Ralf Kronenwett,Mathias Gehrmann,Michael Gnant +26 more
TL;DR: A gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor–positive, HER2-negative breast cancer treated with adjuvant endocrine therapy is developed and validated.
Journal Article
Prevalence of CD44+/CD24−/low Cells in Breast Cancer May Not Be Associated with Clinical Outcome but May Favor Distant Metastasis
Benny K. Abraham,Peter Fritz,Monika McClellan,Petra Hauptvogel,Maria Athelogou,Hiltrud Brauch +5 more
TL;DR: The findings suggest that the prevalence of CD44(+)/CD24(-/low) tumor cells in breast cancer may not be associated with clinical outcome and survival but may favor distant metastasis.
Journal ArticleDOI
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Werner Schroth,Lydia Antoniadou,Peter Fritz,Matthias Schwab,Thomas Muerdter,Ulrich M. Zanger,W. Simon,Michel Eichelbaum,Hiltrud Brauch +8 more
TL;DR: Because genetically determined, impaired tamoxifen metabolism results in worse treatment outcomes, genotyping for CYP2D6 alleles *4, *5, *10, and *41 can identify patients who will have little benefit from adjuvant tamoxIFen therapy.